The first small molecule TYK2 inhibitor was approved by the FDA in 2022 for the treatment of psoriasis, with additional agents under investigation for use in other autoimmune conditions.90, 91, 92 TYK2 mediates signalling through several cytokines that have been linked with T1D pathogenesis, including IFNα, IL-12, and IL-23. This evidence concerns the gene TYK2 and psoriasis.